For years, the pharmaceutical industry has maintained that high prices charged for many medicines in the US are needed to fund R&D, since so many other countries use various means to cap pricing.

Now, though, a new analysis suggests that the additional sales that drug companies generate in the US, compared with four other well-to-do countries, greatly exceeds what they have spent on their global research and development.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • I have a different take. One way to interpret the data is that in the US the drug companies had to actually spend one dollar in R&D to squeeze out an additional 63 cents in revenue, basically the R&D was 63% of the additional sales. Considering that the overall average R&D spend is about 15% of sales what we see here is a perfect example of the Law of Diminishing Returns. Historically we in pharma we have enjoyed as an ROI of 7-10 X R&D costs. Those days are gone, not because of declining revenues but because drug shops have been forced to ramp up R&D spend (which does indeed flow through to higher prices) in order to go after the more elusive diseases.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy